1/30/2017 | SP | New Issue: RBC sells $3.12 million contingent coupon barrier autocallables tied to Amgen, Biogen
|
1/23/2017 | SP | RBC plans contingent coupon barrier autocallables tied to two stocks
|
12/21/2016 | SP | New Issue: RBC prices $15.05 million of 9% STEP Income Securities tied to Biogen
|
11/23/2016 | SP | RBC plans to price 9% STEP Income Securities linked to Biogen
|
1/13/2016 | SP | New Issue: Credit Suisse prices $1 million 10% autocallable yield notes on Biogen
|
9/25/2015 | SP | JPMorgan plans contingent income autocallables linked to Biogen Idec
|
8/11/2015 | SP | New Issue: JPMorgan prices $2.39 million contingent income autocallable securities linked to Biogen Idec
|
8/5/2015 | SP | New Issue: JPMorgan prices $4 million autocallable contingent interest notes linked to Biogen Idec
|
7/31/2015 | SP | JPMorgan plans contingent income autocallables linked to Biogen Idec
|
7/31/2015 | SP | New Issue: UBS prices $100,000 trigger autocallables linked to Biogen Idec
|
7/28/2015 | SP | JPMorgan plans contingent interest autocallables linked to Biogen Idec
|
7/28/2015 | SP | New Issue: HSBC prices $2.6 million contingent income autocallable notes linked to Biogen Idec
|
7/20/2015 | SP | HSBC plans contingent income autocallable notes linked to Biogen
|
7/14/2015 | SP | JPMorgan plans contingent interest autocallable notes linked to Biogen
|
6/30/2015 | SP | New Issue: JPMorgan prices $2.17 million autocallable contingent interest notes linked to Biogen Idec
|
6/11/2015 | SP | New Issue: JPMorgan prices $3.26 million capped return enhanced notes on S&P 500
|
5/19/2015 | SP | New Issue: JPMorgan prices $2.97 million autocallable contingent interest notes linked to Biogen Idec
|
5/13/2015 | SPSW | May kicks off on good note with $446 million priced in 112 offerings; agents sell repeat deals
|
5/12/2015 | SP | JPMorgan plans contingent interest autocallables linked to Biogen Idec
|
5/12/2015 | SP | New Issue: JPMorgan prices $10.94 million autocallable contingent interest notes linked to Biogen Idec
|
5/12/2015 | SP | New Issue: JPMorgan prices $17.19 million contingent income autocallable securities linked to Biogen Idec
|
5/6/2015 | SP | JPMorgan plans contingent interest autocallables linked to Biogen Idec
|
5/5/2015 | SP | New Issue: JPMorgan prices $2.06 million autocallable contingent interest notes linked to Biogen Idec
|
5/1/2015 | SP | JPMorgan plans contingent income autocallables linked to Biogen Idec
|
4/30/2015 | SP | Market Commentary: Citi prices $1.27 million autocallables tied to stocks with eye-catching 31% contingent coupon
|
4/29/2015 | SP | New Issue: JPMorgan prices $2.07 million autocallable contingent interest notes linked to stocks
|
3/19/2015 | SP | New Issue: RBC prices $2.05 million contingent barrier enhanced notes linked to Biogen Idec
|
3/17/2015 | SP | RBC plans contingent barrier enhanced notes linked to Biogen Idec
|
2/10/2015 | SP | New Issue: JPMorgan prices $885,000 autocallable contingent interest notes linked to Biogen Idec
|
2/3/2015 | SP | JPMorgan plans contingent interest autocallables linked to Biogen Idec
|
1/30/2015 | SP | New Issue: UBS prices $250,000 trigger phoenix autocallables linked to Biogen Idec
|
1/26/2015 | SP | New Issue: RBC prices $755,000 phoenix autocallable notes linked to Biogen Idec
|
1/23/2015 | SP | New Issue: JPMorgan prices $1.5 million autocallable contingent interest notes linked to Biogen Idec
|
1/21/2015 | SP | RBC plans phoenix autocallable notes due 2016 linked to Biogen Idec
|
1/20/2015 | SP | New Issue: HSBC prices $1.01 million phoenix quarterly review notes on Biogen Idec
|
1/14/2015 | SP | New Issue: RBC prices $12.16 million 9% STEP Income Securities tied to Biogen Idec
|
1/13/2015 | SP | HSBC to price phoenix quarterly review notes linked to Biogen Idec
|
1/13/2015 | SP | New Issue: JPMorgan prices $8.34 million autocallable contingent interest notes linked to Biogen Idec
|
1/6/2015 | SP | JPMorgan plans autocallable contingent interest notes on Biogen Idec
|
12/23/2014 | SP | RBC plans 9% STEP Income Securities due 2016 linked to Biogen Idec
|
11/26/2014 | SP | New Issue: Barclays prices $26.46 million 14-month Accelerated Return Notes tied to biotech stocks
|
11/26/2014 | SP | New Issue: HSBC prices $1.31 million phoenix quarterly review notes on Biogen Idec
|
11/21/2014 | SP | New Issue: UBS prices $170,000 trigger phoenix autocallables linked to Biogen Idec
|
11/21/2014 | SP | New Issue: UBS prices $129,700 trigger autocallables linked to Biogen Idec
|
11/19/2014 | SP | HSBC to price phoenix quarterly review notes linked to Biogen Idec
|
11/18/2014 | SP | New Issue: RBC prices $3.79 million phoenix autocallable notes on Biogen Idec
|
11/18/2014 | SP | Barclays plans 14-month Accelerated Return Notes tied to biotech stocks
|
11/14/2014 | SP | New Issue: JPMorgan prices $2 million autocallable contingent interest notes on Biogen Idec
|
11/13/2014 | SP | New Issue: UBS prices $125,000 trigger phoenix autocallables linked to Biogen Idec
|
11/12/2014 | SP | RBC to price phoenix autocallable notes linked to Biogen Idec
|
10/31/2014 | SP | HSBC to price 10% autocallable yield notes linked to three stocks
|
10/16/2014 | SP | New Issue: Morgan Stanley prices $1.34 million 7.8% airbag autocallables linked to Biogen Idec
|
10/9/2014 | SP | Morgan Stanley plans 6%-7.8% airbag autocallable yield notes linked to Biogen Idec
|
9/30/2014 | SP | New Issue: RBC prices $105,000 8% reverse convertibles linked to Biogen Idec
|
9/22/2014 | SP | RBC to price 8% reverse convertibles linked to Biogen Idec
|
9/17/2014 | SP | New Issue: RBC prices $527,000 7.9% reverse convertibles linked to Biogen Idec
|
9/12/2014 | SP | RBC to price 7.75% reverse convertibles linked to Biogen Idec
|
8/27/2014 | SP | New Issue: Citigroup prices $1.51 million contingent absolute return autocallables on Biogen Idec
|
8/21/2014 | SP | RBC plans to price 8% reverse convertibles linked to Biogen Idec
|
8/20/2014 | SP | Citi plans contingent absolute return autocallables on Biogen Idec
|
8/20/2014 | SP | New Issue: RBC prices $55,000 7.25% reverse convertibles linked to Biogen Idec
|
8/13/2014 | SP | New Issue: Deutsche Bank prices $2.54 million airbag phoenix autocallable notes on Biogen Idec
|
8/12/2014 | SP | New Issue: HSBC prices $6.43 million contingent income autocallables on Biogen Idec
|
8/8/2014 | SP | RBC to price 7.25% reverse convertibles linked to Biogen Idec
|
8/6/2014 | SP | Deutsche Bank plans airbag phoenix autocallables linked to Biogen Idec
|
8/1/2014 | SP | HSBC to price contingent income autocallables linked to Biogen Idec
|
7/29/2014 | SP | New Issue: Deutsche prices $1.25 million phoenix autocallable securities linked to Biogen Idec
|
7/23/2014 | SPSW | Volume hits $453 million with heavy flow in stock deals amid earnings season, volatility spike
|
7/22/2014 | SP | Deutsche Bank to price phoenix autocallables linked to Biogen Idec
|
7/22/2014 | SP | New Issue: RBC prices $3.89 million phoenix autocallables linked to Biogen Idec
|
7/16/2014 | SP | RBC to price phoenix autocallable notes linked to Biogen Idec
|
7/15/2014 | SP | New Issue: JPMorgan prices $2.53 million autocallable contingent interest notes tied to Biogen Idec
|
7/15/2014 | SP | New Issue: UBS prices $250,000 trigger phoenix autocallables linked to Biogen Idec
|
7/9/2014 | SP | JPMorgan plans to price return notes linked to basket of 16 stocks
|
7/8/2014 | SP | JPMorgan plans contingent interest autocallables linked to Biogen Idec
|
7/8/2014 | SP | New Issue: JPMorgan prices $1.05 million auto callable contingent interest notes linked to Biogen Idec
|
7/1/2014 | SP | New Issue: JPMorgan prices $3.05 million auto callable contingent interest notes linked to Biogen Idec
|
7/1/2014 | SP | JPMorgan plans contingent interest autocallables linked to Biogen Idec
|
6/30/2014 | SP | New Issue: RBC prices $427,000 8.5% reverse convertibles linked to Biogen Idec
|
6/27/2014 | SP | New Issue: JPMorgan prices $2 million autocallable contingent interest notes linked to Biogen Idec
|
6/24/2014 | SP | New Issue: JPMorgan prices $3.06 million auto callable contingent interest notes linked to Biogen Idec
|
6/24/2014 | SP | JPMorgan plans contingent interest autocallables linked to Biogen Idec
|
6/17/2014 | SP | New Issue: RBC prices $25,000 8.25% reverse convertibles linked to Biogen Idec
|
6/17/2014 | SP | JPMorgan plans contingent interest autocallables linked to Biogen Idec
|
6/5/2014 | SP | RBC to price 8.25% reverse convertibles linked to Biogen Idec
|
5/29/2014 | SP | New Issue: RBC prices $64,000 8.75% reverse convertibles linked to Biogen Idec
|
5/27/2014 | SP | New Issue: Citigroup prices $5.27 million contingent coupon autocallables linked to Biogen Idec
|
5/21/2014 | SP | RBC to price 8.75% reverse convertibles linked to Biogen Idec
|
5/20/2014 | SP | New Issue: Citigroup prices $1.43 million contingent absolute return autocallables on Biogen Idec
|
5/16/2014 | SP | New Issue: RBC prices $532,000 10.5% reverse convertibles linked to Biogen Idec
|
5/14/2014 | SP | Citi plans contingent absolute return autocallables linked to Biogen
|
5/13/2014 | SP | New Issue: UBS prices $3.66 million 7.3% airbag autocallables on Biogen
|
5/12/2014 | SP | New Issue: UBS prices $348,000 trigger phoenix autocallables linked to Biogen Idec
|
5/9/2014 | SP | Citigroup plans autocallable contingent coupon notes linked to Biogen
|
5/7/2014 | SP | New Issue: UBS prices $100,000 trigger phoenix autocallables linked to Biogen Idec
|
5/7/2014 | SP | UBS to price 6%-7.5% airbag autocallables linked to Biogen Idec
|
5/6/2014 | SP | New Issue: JPMorgan prices $14.75 million contingent income autocallables on Biogen Idec
|
5/6/2014 | SP | RBC to price 10.5% reverse convertibles linked to Biogen Idec
|
4/29/2014 | SP | New Issue: JPMorgan prices $1.65 million 8.5% upside autocallable reverse exchangeables on Biogen Idec
|
4/25/2014 | SP | JPMorgan plans contingent income autocallables linked to Biogen Idec
|
4/21/2014 | SP | RBC to price 8.25% reverse convertibles linked to Biogen Idec
|
4/17/2014 | SP | New Issue: RBC prices $431,000 9.75% reverse convertibles linked to Biogen Idec
|
4/3/2014 | SP | New Issue: UBS prices $312,000 trigger phoenix autocallables linked to Biogen Idec
|
4/2/2014 | SP | RBC to price 9.75% reverse convertibles linked to Biogen Idec
|
4/1/2014 | SP | New Issue: UBS prices $250,000 trigger phoenix autocallables linked to Biogen Idec
|
3/11/2014 | SP | New Issue: UBS prices $250,000 trigger phoenix autocallables linked to Biogen Idec
|
2/26/2014 | BKIG | Moody's upgrades Biogen to Baa1
|
2/11/2014 | SP | New Issue: RBC prices $1.62 million trigger phoenix autocallables linked to Biogen
|
2/5/2014 | SP | RBC to price trigger phoenix autocallables linked to Biogen Idec
|
12/12/2013 | SP | New Issue: HSBC prices $12.88 million 9% STEP Income notes linked to Biogen Idec
|
12/3/2013 | SP | HSBC plans one-year 9% STEP Income Securities tied to Biogen Idec
|
11/15/2013 | SP | New Issue: UBS prices $126,530 trigger phoenix autocallables linked to Biogen Idec
|
10/8/2013 | SP | New Issue: RBC prices $384,000 contingent absolute return autocallables linked to Biogen
|
10/4/2013 | SP | New Issue: UBS prices $109,960 trigger phoenix autocallables linked to Biogen Idec
|
10/2/2013 | SP | RBC plans contingent absolute return autocallables on Biogen Idec
|
9/17/2013 | SP | New Issue: RBC prices $47,000 10% reverse convertibles linked to Biogen Idec
|
9/5/2013 | SP | RBC to price 10% reverse convertibles linked to Biogen Idec
|
8/20/2013 | SP | New Issue: UBS prices $113,890 trigger phoenix autocallables linked to Biogen Idec
|
8/6/2013 | SP | New Issue: JPMorgan prices $402,000 contingent absolute return autocallables linked to Biogen
|
8/1/2013 | SP | JPMorgan plans contingent absolute return autocallables tied to Biogen
|
7/22/2013 | SP | RBC to price 11% reverse convertibles linked to Biogen Idec
|
6/28/2013 | SP | New Issue: RBC prices $45,000 11% reverse convertibles linked to Biogen Idec
|
6/26/2013 | SP | New Issue: UBS sells $1.16 million 7.4% airbag autocallable notes linked to Biogen
|
6/19/2013 | SP | RBC to price 11% reverse convertibles linked to Biogen Idec
|
6/19/2013 | SP | UBS to price 6%-7.75% airbag autocallables linked to Biogen Idec
|
6/17/2013 | SP | New Issue: RBC prices $25,000 10% reverse convertibles linked to Biogen Idec
|
6/17/2013 | SP | New Issue: RBC prices $55,000 12.75% reverse convertibles linked to Biogen Idec
|
6/5/2013 | SP | RBC to price 10% reverse convertibles linked to Biogen Idec
|
4/17/2013 | BKIG | S&P lifts Biogen Idec
|
3/28/2013 | BKIG | Moody's lifts Biogen Idec view to positive
|
3/14/2013 | BK | Biogen gets $750 million revolver in connection with Tysabri purchase
|
3/19/2012 | IG | Moody's ups Biogen to Baa2
|
8/16/2011 | IG | Moody's ups Biogen to positive
|
11/3/2010 | IG | Moody's: Biogen Idec unchanged
|
12/16/2009 | SS | Facet Biotech shareholder permitted to increase ownership to 20%
|
12/15/2009 | SS | Biogen Idec says it will seek to replace Facet's board if necessary
|
12/15/2009 | SS | Market Commentary: Biogen odds high on Facet war; Peet's unlikely to win deal; Kraft's takeover chances improve
|
12/11/2009 | SS | Facet investor buys 369,059 shares, lifts ownership interest to 5.5%
|
12/11/2009 | SS | Market Commentary: Biogen sticks to same bid; more deals likely for Varco; oil deals expected to focus on equity
|
12/11/2009 | SS | Biogen Idec will not extend offer for Facet's shares beyond Wednesday
|
12/10/2009 | SS | Facet board recommends against Biogen Idec's 'best-and-final' offer
|
12/10/2009 | SS | Market Commentary: Analyst: New drug behind Facet plans; Time likely to keep printing; Cliffs raises Freewest bid
|
12/4/2009 | SS | Market Commentary: Kraft set on Cadbury bid; Facet unlikely to gain other offers; Cisco wins control of Tandberg
|
12/3/2009 | SS | Biogen Idec makes 'best-and-final' offer of $17.50 per share for Facet
|
10/16/2009 | SS | Biogen Idec extends $14.50-per-share tender offer for Facet Biotech
|
10/16/2009 | SS | Market Commentary: Market expects higher Facet bid; Cisco may stick to offer terms; Adaptec holds deal interest
|
10/15/2009 | SS | Market Commentary: Reviews unlikely to stop BJ Services buyout; Acorda sparks sale talk; Invesco deal expected
|
10/1/2009 | SS | Facet Biotech delays distribution date under stockholder rights plan
|
10/1/2009 | SS | Market Commentary: Radvision likely to seek buyer on Cisco snub; CF readies for Terra war; bid fails to wow Facet
|
9/21/2009 | SS | Biogen Idec begins $14.50-per-share tender offer for Facet Biotech
|
9/21/2009 | SS | Market Commentary: Dell hints at future deals; Odyssey Re buyout looks set; Biogen expected to increase Facet bid
|
9/14/2009 | SS | Elan cures breach; Johnson & Johnson drops price for interest in company
|
9/9/2009 | SS | Facet Biotech investor drops stake, weighs in on Biogen Idec offer
|
9/8/2009 | SS | Facet Biotech rejects Biogen Idec offer, sets shareholder rights plan
|
9/4/2009 | SS | Biogen Idec lowers bid for Facet Biotech to $14.50 cash per share
|
9/4/2009 | SS | Market Commentary: Biogen bids low for Facet; Sun deal seen closing by year end; Metavante buyout set to close
|
6/11/2009 | SS | Biogen Idec looking to move forward upon election of new directors
|
6/9/2009 | SS | Biogen Idec board of directors now includes two of Icahn's nominees
|
6/5/2009 | SS | Market Commentary: Icahn burrows into Amylin, Biogen; NRG sets date for Exelon clash; Cougar buyout on track
|
6/4/2009 | SS | Biogen Idec says election results for final director too close to call
|
6/3/2009 | SS | Icahn accuses Biogen Idec of trying to hijack director election
|
5/28/2009 | SS | Proxy firm backs two of Icahn's nominees for election to Biogen board
|
5/26/2009 | SS | Biogen Idec nominees receive full support of two proxy advisory firms
|
5/26/2009 | SS | Market Commentary: Target fight heats up; Biogen split seen to up sale potential; Emulex shares trade above bid
|
4/27/2009 | SS | Biogen Idec asks shareholders to reject Icahn's nominees on June 3
|
4/7/2009 | SS | Market Commentary: Spread widens on Wyeth stock; Biogen jumps on buyout talk; Cubist makes difficult takeover target
|
2/9/2009 | SS | Icahn's proposals take advantage of new North Dakota law that removes anti-takeover provisions
|
2/9/2009 | SS | Market Commentary: Biogen ripe for $76-a-share buyout; Genentech buyout bid opens; Rohm & Haas pressures Dow Chemical
|
2/6/2009 | SS | Market Commentary: Icahn's move on Biogen seen as sale prep; Abbott buyout on track; TD Ameritrade shares up on new stake
|
2/6/2009 | SS | Icahn seeks to place four on board of Biogen Idec
|
1/16/2009 | SS | Biogen Idec terminates rights plan
|
12/4/2008 | IG | S&P lifts Biogen
|
9/29/2008 | IG | S&P: Biogen on positive watch
|
8/11/2008 | SS | Icahn buys 5 million shares of Biogen Idec
|
8/6/2008 | SP | New Issue: ABN Amro prices $3.4 million 10.02% reverse convertibles linked to Biogen Idec
|
7/9/2008 | SS | Independent inspector confirms election of Biogen Idec's four director nominees, rejection of Icahn's slate
|
6/19/2008 | SS | Biogen Idec claims victory in proxy battle with Icahn
|
6/10/2008 | SS | Two proxy advisory firms back Biogen Idec nominees for election on June 19
|
5/8/2008 | SS | Biogen Idec asks shareholders to reject Icahn's nominees and elect company's slate
|
2/28/2008 | IG | New Issue: Biogen prices $1 billion of notes in five-, 10-year tranches
|
2/28/2008 | IG | Market Commentary: Archer Daniels, Colonial BancGroup, Hartford, Biogen price; negative headlines end micro-rally
|
2/27/2008 | IG | Market Commentary: Citi, Avon, Clorox, Computer Sciences, Allstate price; Colonial Bank plans issue; Biogen issue hits snag
|
2/26/2008 | IG | Biogen Idec to offer five-, 10-year notes; pricing likely Wednesday
|
2/26/2008 | IG | Biogen files automatic shelf
|
2/26/2008 | IG | S&P rates Biogen Idec notes BBB
|
2/26/2008 | IG | Moody's gives Biogen Idec note Baa3
|
2/26/2008 | IG | Market Commentary: McDonald's, Honeywell, PG&E, ING, SunTrust, KfW, UST, Fifth Third price; jammed calendar ahead
|
1/28/2008 | SS | Icahn seeks representation on Biogen Idec board
|
12/12/2007 | SS | Biogen completes review process with no definitive offers
|
10/12/2007 | SS | Biogen to explore merger opportunities
|
7/2/2007 | SS | Biogen settles $3 billion stock tender offer
|
6/27/2007 | SS | Biogen Idec to accept more than 56 million shares in tender offer
|
5/29/2007 | BK | Biogen plans $1.5 billion term loan for stock tender offer
|
4/23/2007 | SS | Market Commentary: MedImmune deal rekindles buzz of biotech buyouts; Genesco gains; Vonage eyed
|
12/22/2006 | SP | New Issue: Barclays sells $1 million 8% reverse convertibles linked to Biogen
|
12/6/2006 | SP | Barclays to price 8% reverse convertibles linked to Biogen Idec
|
12/4/2006 | SP | Barclays to price 8% reverse convertibles linked to Biogen Idec
|
11/7/2006 | BT | Market Commentary: Catalyst cuts IPO price in half; Cytogen off on PIPE; Targeted Genetics gains 35%; Iomai better
|
11/1/2006 | BT | Jefferies puts Biogen on hold
|
11/1/2006 | BT | Biogen at outperform by RBC
|
10/31/2006 | BT | Biogen reports $703 million Q3 revenues, strong Tysabri launch
|
10/31/2006 | BT | Merrill keeps Biogen at neutral
|
10/27/2006 | BT | Biogen still on hold by Jefferies
|
10/27/2006 | BT | Biogen remains neutral by Merrill
|
10/6/2006 | BT | Market Commentary: Acorda up 10% as Elan, Biogen ease on Tysabri news; Panacos up on takeover; Memory up on PIPE
|
9/29/2006 | BT | Biogen announces three Tysabri trial results at European MS conference
|
9/20/2006 | BT | Biogen Idec, Alnylam to develop RNAi therapeutics for treatment of PML
|
9/18/2006 | BT | Biogen reports galiximab in phase 3; lumiliximab scheduled to follow in early 2007
|
9/14/2006 | BT | Market Commentary: Threshold, Discovery Labs gain on widespread deal speculation; Curis better; Genzyme gains 3%
|
9/14/2006 | BT | Biogen, mondoBiotech to develop hypertension drug Aviptadil
|
8/30/2006 | BT | Market Commentary: AnorMED snubs Genzyme bid; PDL higher as Roche backs out; Vasogen zooms 42%; Adeza up
|
8/28/2006 | BT | Genentech and Biogen say phase 2 study of Rituxan for MS met primary endpoint
|
8/28/2006 | BT | Merrill maintains Biogen at neutral
|
8/28/2006 | BT | Market Commentary: Discovery Partners up 9% on MedImmune, Infinity pact; EPIX plunges; Sinovac soars; PDL up
|
8/15/2006 | BT | Biogen cites potential new pathway in rheumatoid arthritis disease process
|
7/27/2006 | BT | Biogen Idec on hold by Jefferies
|
7/26/2006 | BT | Biogen reports $171 million GAAP net loss for second quarter; Avonex approved in Japan
|
7/26/2006 | BT | Biogen maintained at neutral by Merrill
|
7/26/2006 | BT | RBC rates Biogen at outperform
|
7/25/2006 | BT | Biogen Idec on hold by Jefferies
|
7/24/2006 | BT | Biogen Idec, Elan say Tysabri available to treat relapsing forms of multiple sclerosis
|
6/29/2006 | BT | Biogen, Elan receive EU approval for Tysabri in treatment of multiple sclerosis
|
6/22/2006 | BT | Genentech, Biogen say Rituxan reduces joint erosion, damage in arthritis patients
|
6/9/2006 | BT | Biogen Idec on hold by Jefferies
|
6/6/2006 | BT | PDL Biopharma, Biogen say early data from volociximab trials show antitumor activity
|
6/6/2006 | BT | Biogen, Elan expect data, prescription program to advance Tysabri reintroduction
|
6/5/2006 | BT | Biogen, Elan receive FDA approval to reintroduce Tysabri for MS
|
6/5/2006 | BT | Market Commentary: Genelabs stock skyrockets on Novartis collaboration; Antigenics stock falls on phase 3 Oncophage data
|
5/31/2006 | BT | Biogen Idec to acquire Fumapharm
|
5/30/2006 | BT | Biogen's oral compound BG-12 achieves primary endpoint in multiple sclerosis study
|
5/18/2006 | BT | RBC quarterly biotechnology update
|
5/18/2006 | BT | Market Commentary: Neurocrine piles on more losses; DOV adds back 10%; Celgene sees buying on dip; Exelixis up
|
5/3/2006 | BT | Biogen to acquire Conforma for $150 million
|
4/28/2006 | BT | Biogen Idec, Elan: European committee issues positive opinion for Tysabri to treat multiple sclerosis
|
4/28/2006 | BT | Biogen on hold by Jefferies
|
4/28/2006 | BT | Merrill maintains Biogen at neutral
|
4/26/2006 | BT | Biogen Idec reports Q1 EPS of $0.55, predicts EPS of $1.95-$2.10 for 2006
|
4/26/2006 | BT | Biogen stays at neutral by Merrill
|
4/25/2006 | BT | Biogen at hold by Jefferies
|
4/6/2006 | BT | Biogen Idec, Elan find quality of life benefits in phase 3 trial of Tysabri for MS
|
4/3/2006 | BT | Astellas to buy Amevive from Biogen Idec
|
3/30/2006 | BT | Genentech, Biogen submit sBLA for Rituxan in non-Hodgkin's lymphoma
|
3/29/2006 | BT | Biogen, Elan resume Tysabri clinical trial
|
3/22/2006 | BT | Biogen Idec, Elan say FDA needs more time to review Tysabri risk plan for multiple sclerosis
|
3/22/2006 | BT | Merrill maintains Biogen at neutral
|
3/22/2006 | BT | Market Commentary: Cephalon seesaws; Nabi zooms; Endo drops; Insmed off; Elan, Biogen drop; King launches deal
|
3/9/2006 | BT | Biogen IDEC kept at neutral by Merrill
|
3/9/2006 | BT | Biogen IDEC on hold by Jefferies
|
3/9/2006 | BT | Market Commentary: NPS Pharma weak ahead of FDA; Dyax plunges; Insmed up slightly; Vertex dives; Elan off, Biogen up
|
3/8/2006 | BT | Biogen, Elan say FDA committee votes to reintroduce Tysabri for multiple sclerosis
|
3/8/2006 | BT | Merrill keeps Biogen neutral
|
3/8/2006 | BT | Market Commentary: Alexza IPO gets off; Cepheid off; Dyax deal seen; Elan, Biogen up; Neurocrine shakes off trial miss
|
3/1/2006 | BT | Genentech, Biogen Idec: FDA approves Rituxan for rheumatoid arthritis
|
3/1/2006 | BT | Merrill puts BioGen at neutral
|
3/1/2006 | BT | Biogen, Elan give update on trials, safety study for multiple sclerosis drug Tysabri
|
2/28/2006 | BT | Market Commentary: Generex recoils along with most flu names; King Pharma clubbed; Elan, Biogen hit by analyst poll
|
2/22/2006 | BT | S&P lifts Biogen Idec from junk
|
2/17/2006 | BT | Biogen on hold by Jefferies
|
2/16/2006 | BT | Market Commentary: Adolor up on heavy volume after deal; Avigen sinks; Biogen, Elan react to Tysabri news; Onyx slips
|
2/16/2006 | BT | Biogen kept at neutral by Merrill
|
2/16/2006 | BT | Biogen at hold by Jefferies
|
2/15/2006 | BT | Biogen, Elan announce FDA lifts hold on Tysabri trial for MS
|
2/13/2006 | BT | Biogen kept at hold by Jefferies
|
2/10/2006 | BT | Genentech, Biogen receive FDA OK for Rituxan Plus CHOP for non-Hodgkin's lymphoma
|
1/23/2006 | BT | Biogen, Elan say FDA to review Tysabri for multiple sclerosis in March
|
1/23/2006 | BT | Biogen given hold rating by Jefferies
|
1/11/2006 | BT | Market Commentary: PDL, OSI Pharma, Biogen dive; Altus IPO launches, Vertex eases; Novogen shelves Glycotex IPO
|
1/9/2006 | BT | Biogen Idec, Fumapharm's multiple sclerosis drug reduces brain lesions, study says
|
12/13/2005 | BT | Biogen evaluates Zevalin as potential lymphoma cocktail
|
11/18/2005 | CV | Market Commentary: Sonic, CompuCredit edge higher; Doral Financial surges amid rumors; Protein Design gains
|
11/18/2005 | BT | Market Commentary: Onyx gains after 'well-priced' deal; Elan, Biogen rise; Protein Design Labs up; Cubist higher
|
11/17/2005 | BT | Biogen Idec, Elan say FDA accepts Tysabri application for priority review to treat multiple sclerosis
|
11/17/2005 | BT | Biogen Idec says its scientists discover central nervous system receptor linked to Parkinson's disease
|
11/15/2005 | BT | Biogen Idec's Amevive may alleviate psoriasis symptoms for nearly a year, study says
|
10/31/2005 | BT | Biogen Idec, Genentech receive FDA priority review for Rituxan treatment of rheumatoid arthritis
|
10/28/2005 | BT | Jefferies maintains Biogen at hold
|
10/27/2005 | BT | Jefferies maintains Biogen at hold
|
10/27/2005 | BT | Merrill maintains Biogen at neutral
|
10/25/2005 | BT | Jefferies maintains Biogen Idec at hold rating
|
10/17/2005 | BT | No new PML cases in patients taking Tysabri, Elan, Biogen say
|
10/17/2005 | BT | Market Commentary: Chiron falls big after closing bell; Biogen, Elan gain; Cephalon up
|
10/3/2005 | BT | Amylin sales looking up as Biogen may face downside, Merrill report says
|
9/27/2005 | BT | Biogen maintained by Merrill at neutral
|
9/27/2005 | BT | Biogen maintained by Jefferies at hold
|
9/27/2005 | BT | Market Commentary: Sunesis sinks after below-range IPO; Biogen, Elan bounce then retreat; Genentech sharply lower
|
9/13/2005 | BT | Market Commentary: Immunomedics up; OSI rebounds; Celgene retreats; Protein Design Labs, Novavax, Cephalon all up
|
9/9/2005 | BT | Biogen maintained by Merrill Lynch at neutral
|
9/9/2005 | BT | Market Commentary: Genomic talk surfaces; Voyager files IPO; Elan joins Biogen fall on restructuring; Sepracor lifted
|
9/9/2005 | BT | Biogen kept by Bear Stearns at underperform
|
9/9/2005 | BT | Biogen cut by Thomas Weisel to underperform
|
9/7/2005 | BT | Mature U.S. biotechs have stronger credit than industrials but weaker than Big Pharma, S&P says
|
9/1/2005 | BT | Targeted Genetics amends Biogen funding agreement, pushing out debt repayments
|
8/11/2005 | BT | Market Commentary: Coley, China Medical ease back; Mpex announces venture capital; Kosan slips; Elan issues retreat
|
8/9/2005 | BT | Market Commentary: Elan, Biogen Idec up on Tysabri update; Human Genome convertible rises; Celgene, King Pharma gain
|
8/3/2005 | BT | Biogen Idec maintained by Merrill at neutral
|
8/3/2005 | BT | Market Commentary: Lilly launches $1.5 billion floater; Human Genome $230 million convert at bat; MannKind taps PIPEs
|
7/28/2005 | BT | Biogen estimates raised by Jefferies
|
7/27/2005 | BT | Market Commentary: Theravance rises; NPS Pharma off; Advanced Life Sciences IPO on for Thursday; Elan, Biogen slightly higher
|
7/27/2005 | BT | Biogen estimates raised by Merrill Lynch
|
7/26/2005 | BT | Market Commentary: Glaxo pact helps Human Genome; Mylan, Impax up with Teva, Ivax; Elan, Biogen up on Tysabri plans
|
7/11/2005 | BT | Merrill biotech analysts see interest in sector ahead of second quarter earnings
|
5/10/2005 | CV | New Issue: ABN Amro sells $1.275 million 10% reverse exchangeables linked to Biogen Idec
|
5/3/2005 | CV | Biogen says 99.2% of LYONs put back to company
|
3/7/2005 | CV | Market Commentary: Genworth synthetic coming; Cell Therapeutics dives; Celgene rises; Saks bagged up; Lions Gate higher
|
3/4/2005 | CV | Market Commentary: Allied Waste trades up from par; Nash Finch launches deal; Elan slides, Biogen steadier on news
|
3/1/2005 | CV | Market Commentary: Charter falters on earnings; XM Satellite up as volatility play; Ford, GM lower but Chrysler up
|
2/28/2005 | CV | Market Commentary: Elan hurt, Biogen stable; Teva up, Schering slips; King trips; Yellow skids; Manpower lower; Saks off
|
11/24/2004 | CV | S&P: Biogen on watch positive
|
10/18/2004 | CV | Market Commentary: Sirius convertibles up on Ford news; Elan active, edges up on Biogen buzz; CNet gains
|
10/11/2004 | CV | Market Commentary: Northwest, Delta lead lower on fuel prices, pilot contract concerns; drug paper higher
|
9/30/2004 | CV | Market Commentary: Ford, GM convertibles see little traffic ahead of Sept sales; Schering-Plough shoots up
|
9/30/2004 | CV | New Issue: Morgan Stanley prices $11 million 7% Sparqs exchangeable for Biogen
|
7/26/2004 | CV | Market Commentary: King Pharma soars on merger; Boise Cascade higher on split; Marshall & Ilsley deal emerges
|
3/3/2004 | CV | S&P: Biogen Idec unaffected
|
3/2/2004 | CV | Market Commentary: Avnet, Bell Micro gain; Amdocs slips; in gray, PSS bid plus 1 point, First Horizon at plus 0.25 point
|
12/2/2003 | CV | S&P ups Biogen Idec senior debt to BB+
|